Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Each year in the UK, over 300 patients are diagnosed with myelofibrosis,  a blood cancer associated with debilitating symptoms including extreme fatigue, pain, weakness and shortness of breath. Around 10-20% of patients go on to develop acute myeloid leukaemia, with median survival from the time of diagnosis just 2 years for patients with high-risk disease.

Stem cell transplant are the only cure for myelofibrosis, but this is only suitable for a small minority of younger patients who don't have other conditions as well. Instead, the standard NHS care for the illness is treatment with a drug called ruxolitnib, but many patients do not respond to this treatment.

Professor Mead said "The PROMise study is a really exciting study that has just opened in the UK and will be opening across 15 centres. This is introducing a new treatment called PLX2853, in combination with ruxolitininb, for patients with MF (myelofibrosis)."

Read the full story on the Radcliffe Department of Medicine website.

Similar stories

NHS garden in full bloom at RHS Chelsea Flower Show

The sun was shining for the RHS Chelsea Flower show press day earlier this week. One garden in particular bloomed particularly brightly, with the 'Finding Our Way: An NHS Tribute Garden' getting plenty of attention.

University of Oxford launches Podium Analytics Institute for Youth Sports Medicine and Technology

Oxford University has been selected as the home of the new Podium Analytics Institute for Youth Sports Medicine and Technology. This will be the world’s first academic Institute focused on young athletes’ safety and lifelong health and will combine Oxford’s longstanding tradition in sports and education with the very best of science, medicine, and technology.

QCovid highly commended for ‘best use of technology in Patient Safety’ at the 2021 HSJ Patient Safety Awards

Professor Julia Hippisley-Cox and her team in Nuffield Department of Primary Care Health Sciences have been Highly Commended in the ‘Best use of technology in Patient Safety’ category for the QCovid risk calculator at this year’s Health Service Journal Patient Safety Awards.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have developed a new set of guidelines for reporting mediation analyses in health research.

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.